Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Philippe Moreau; María‐Victoria Mateos; James R. Berenson; Katja Weisel; Antonio Lazzaro; Kevin Song; Meletios A Dimopoulos; Mei Huang; Anita Zahlten‐Kumeli; A. Keith Stewart

doi:10.1016/s1470-2045(18)30354-1

Article2018

Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

Philippe Moreau, Shaji Kumar, Ralph V. Boccia, Shinsuke Iida, Hartmut Goldschmidt, Kim Cocks, Anita Zahlten‐Kumeli, Emre Yücel, Sumeet Panjabi, Meletios A Dimopoulos

Article2020

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

Meletios A Dimopoulos, Rubén Niesvizky, Katja Weisel, David S. Siegel, Roman Hájek, María‐Victoria Mateos, Michèle Cavo, Mei Huang, Anita Zahlten‐Kumeli, Philippe Moreau

Article2018

Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

María‐Victoria Mateos, Philippe Moreau, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten‐Kumeli, A. Keith Stewart

Article2018

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Meletios A Dimopoulos, Rubén Niesvizky, Philippe Moreau, David S. Siegel, Roman Hájek, María‐Victoria Mateos, Michèle Cavo, Mei Huang, Anita Zahlten‐Kumeli, Katja Weisel

Article2019

PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Philippe Moreau, A. Keith Stewart, Meletios A Dimopoulos, David S. Siegel, Thierry Façon, James Berenson, Noopur Raje, Jesús G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, M.‐V. Mateos

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Discussion(0)

Related publications

Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA